Skip Nav Destination
Issues
15 December 2008
-
Cover Image
Cover Image
mTOR inhibition by rapamycin causes tumor regression in a chemically induced squamous cell carcinoma model. Shown here is the immunodetection of phosphorylated ribosomal S6 protein (pS6, red) and E-cadherin (green) labeling the tumor cells in an early squamous tumoral lesion arising in the skin of mice treated with DMBA followed by TPA (nuclei are stained with DAPI, blue). Immunofluorescent staining of pS6 reflects the widespread activation of mTOR in this chemically-induced skin cancer lesion. For further details, please see Amornphimoltham and coworkers on page 8094 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
CCR Translations
CCR Practice of Translational Oncology
Molecular Pathways
CCR Special Focus
Human Cancer Biology
DNA Copy-Number Alterations Underlie Gene Expression Differences between Microsatellite Stable and Unstable Colorectal Cancers
Robert N. Jorissen; Lara Lipton; Peter Gibbs; Matthew Chapman; Jayesh Desai; Ian T. Jones; Timothy J. Yeatman; Philip East; Ian P.M. Tomlinson; Hein W. Verspaget; Lauri A. Aaltonen; Mogens Kruhøffer; Torben F. Ørntoft; Claus Lindbjerg Andersen; Oliver M. Sieber
Cancer Therapy: Preclinical
Second-Generation Anti–Carcinoembryonic Antigen Designer T Cells Resist Activation-Induced Cell Death, Proliferate on Tumor Contact, Secrete Cytokines, and Exhibit Superior Antitumor Activity In vivo: A Preclinical Evaluation
Peter C.R. Emtage; Agnes S.Y. Lo; Erica M. Gomes; David L. Liu; Rosa M. Gonzalo-Daganzo; Richard P. Junghans
Nuclear Factor-κB p65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells
Xue Pan; Thiruvengadam Arumugam; Tameyoshi Yamamoto; Pavel A. Levin; Vijaya Ramachandran; Baoan Ji; Gabriel Lopez-Berestein; Pablo E. Vivas-Mejia; Anil K. Sood; David J. McConkey; Craig D. Logsdon
Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the In vivo Elimination of Methotrexate and its Main Toxic Metabolite 7-hydroxymethotrexate
Maria L.H. Vlaming; Zeliha Pala; Anita van Esch; Els Wagenaar; Olaf van Tellingen; Dirk R. de Waart; Ronald P.J. Oude Elferink; Koen van de Wetering; Alfred H. Schinkel
Inhibition of Melanoma Growth by Targeting of Antigen to Dendritic Cells via an Anti-DEC-205 Single-Chain Fragment Variable Molecule
Theron S. Johnson; Karsten Mahnke; Volker Storn; Kurt Schönfeld; Sabine Ring; Dirk M. Nettelbeck; Hidde J. Haisma; Fabrice Le Gall; Roland E. Kontermann; Alexander H. Enk
Reduction of Human Melanoma Tumor Growth in Severe Combined Immunodeficient Mice by Passive Transfer of Antibodies Induced by a High Molecular Weight Melanoma-Associated Antigen Mimotope Vaccine
Stefan Wagner; Clemens Krepler; Dorothee Allwardt; Julia Latzka; Sabine Strommer; Otto Scheiner; Hubert Pehamberger; Ursula Wiedermann; Christine Hafner; Heimo Breiteneder
Imaging, Diagnosis, Prognosis
Allelic Imbalance Analysis Using a Single-Nucleotide Polymorphism Microarray for the Detection of Bladder Cancer Recurrence
Marieke J.H. Coenen; Martine Ploeg; Mascha M.V.A.P. Schijvenaars; Erik B. Cornel; Herbert F.M. Karthaus; Hans Scheffer; J. Alfred Witjes; Barbara Franke; Lambertus A.L.M. Kiemeney
The Incidence, Correlation with Tumor-Infiltrating Inflammation, and Prognosis of Phosphorylated STAT3 Expression in Human Gliomas
Mohamed Abou-Ghazal; David S. Yang; Wei Qiao; Chantal Reina-Ortiz; Jun Wei; Ling-Yuan Kong; Gregory N. Fuller; Nobuyoshi Hiraoka; Waldemar Priebe; Raymond Sawaya; Amy B. Heimberger
Identification of PMF1 Methylation in Association with Bladder Cancer Progression
Ainel Aleman; Virginia Cebrian; Miguel Alvarez; Virginia Lopez; Esteban Orenes; Lidia Lopez-Serra; Ferran Algaba; Joaquin Bellmunt; Antonio López-Beltrán; Pilar Gonzalez-Peramato; Carlos Cordon-Cardo; Javier García; Javier García del Muro; Manel Esteller; Marta Sánchez-Carbayo
Cancer Therapy: Clinical
Protein Expression Profiling in Esophageal Adenocarcinoma Patients Indicates Association of Heat-Shock Protein 27 Expression and Chemotherapy Response
Rupert Langer; Katja Ott; Katja Specht; Karen Becker; Florian Lordick; Maria Burian; Ken Herrmann; Andre Schrattenholz; Michael A. Cahill; Markus Schwaiger; Heinz Hofler; Hans-Jurgen Wester
A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies
Aaron D. Schimmer; Susan O'Brien; Hagop Kantarjian; Joseph Brandwein; Bruce D. Cheson; Mark D. Minden; Karen Yee; Farhad Ravandi; Francis Giles; Andre Schuh; Vikas Gupta; Michael Andreeff; Charles Koller; Hong Chang; Suzanne Kamel-Reid; Mark Berger; Jean Viallet; Gautam Borthakur
Letters to the Editor
Acknowledgment to Reviewers
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds